Literature DB >> 29232548

Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search.

Geoffrey I Shapiro1.   

Abstract

In this issue of Cancer Cell, Gong et al. have analyzed the sensitivity of 560 cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined cancers with specific genomic "D-cyclin activating features (DCAF)" as particularly vulnerable. These findings will facilitate patient selection as development of this drug class continues.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29232548     DOI： 10.1016/j.ccell.2017.11.013

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  6 in total

Review 1.  Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers.

Authors:  Erik S Knudsen; Geoffrey I Shapiro; Khandan Keyomarsi
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-05

Review 2.  The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer.

Authors:  Scott F Schoninger; Stacy W Blain
Journal:  Mol Cancer Ther       Date:  2020-01       Impact factor: 6.261

3.  Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia.

Authors:  Hidemasa Matsuo; Kenichi Yoshida; Kazutaka Fukumura; Kana Nakatani; Yuki Noguchi; Saho Takasaki; Mina Noura; Yusuke Shiozawa; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Ai Okada; Yasuhito Nannya; June Takeda; Hiroo Ueno; Norio Shiba; Genki Yamato; Hiroshi Handa; Yuichiro Ono; Nobuhiro Hiramoto; Takayuki Ishikawa; Kensuke Usuki; Ken Ishiyama; Shuichi Miyawaki; Hidehiro Itonaga; Yasushi Miyazaki; Machiko Kawamura; Hiroki Yamaguchi; Nobutaka Kiyokawa; Daisuke Tomizawa; Takashi Taga; Akio Tawa; Yasuhide Hayashi; Hiroyuki Mano; Satoru Miyano; Yasuhiko Kamikubo; Seishi Ogawa; Souichi Adachi
Journal:  Blood Adv       Date:  2018-11-13

4.  PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence.

Authors:  Mary E Klein; Mark A Dickson; Cristina Antonescu; Li-Xuan Qin; Scott J Dooley; Afsar Barlas; Katia Manova; Gary K Schwartz; Aimee M Crago; Samuel Singer; Andrew Koff; William D Tap
Journal:  Oncogene       Date:  2018-05-23       Impact factor: 9.867

5.  Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns.

Authors:  Lidia Mateo; Miquel Duran-Frigola; Albert Gris-Oliver; Marta Palafox; Maurizio Scaltriti; Pedram Razavi; Sarat Chandarlapaty; Joaquin Arribas; Meritxell Bellet; Violeta Serra; Patrick Aloy
Journal:  Genome Med       Date:  2020-09-09       Impact factor: 11.117

6.  Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens.

Authors:  Shumei Kato; Ryosuke Okamura; Jacob J Adashek; Noor Khalid; Suzanna Lee; Van Nguyen; Jason K Sicklick; Razelle Kurzrock
Journal:  JCI Insight       Date:  2021-01-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.